MARKET OVERVIEW- NORTH AMERICA CELL FREE PROTEIN EXPRESSION MARKET
Cell-free protein expression (CFPE) process is described as the production of recombinant proteins in solution using biomolecular translation machinery extracted from cells. This method is widely used for the expansion of genetic code, assembly of viruses, and in metabolic engineering for the production of toxic and complex proteins. It has emerged as a potent technology for high-throughput production of membrane proteins, enzymes, and therapeutics. The cell-free protein expression method is time efficient and convenient, allows the incorporation of non-natural amino acids, and provides enhanced stability and specificity. The growth of the North America Cell Free Protein Expression market is driven by an increasing elderly population, and the rise in prevalence of cancer and infectious diseases in countries like United States and Canada, Furthermore, rising investments in drug discovery research are expected to positively contribute to the growth of the market.
MARKET DRIVERS
The growth of the market is driven by an increasing geriatric population along with a rise in the prevalence of chronic disease such as cancer, diabetes, cardiovascular disease, and others. According to the U.S. Census Bureau, more than 56 million adults ages 65 and older live in the United States, accounting for about 16.9% of the nation's population. By 2030, when the last of the baby boomer generation ages into older adulthood, it is projected that there will be more than 73.1 million older adults. The rise in geriatric population has led to a rise in the prevalence of chronic diseases. According to the CDC, six in ten Americans live with at least one chronic disease, like heart disease and stroke, cancer, or diabetes. According to the U.S. National Center for Health Statistics, about 40 million Americans are limited in their usual activities due to one or more chronic health conditions.
Thus, rising cases of chronic disease create a demand for personalized medicine which can be achieved using cell-free protein expression. This is expected to drive the growth of the market over the forecast period. Furthermore, the rise in utilization of cell-free protein expression in the pharmaceutical industry for developing protein-based therapeutics, such as antibodies, antimicrobials, and cytokines, for treating cancer and infectious diseases is expected to positively impact the growth of the market.
MARKET OPPORTUNITIES
The rise in innovative research projects is expected to provide ample opportunity for the market. For instance, in April 2021 Promega announced the opening of the newly constructed R&D facility (Kornberg Center) on its Fitchburg, WI campus. The building will support essential technology and product development in genetic identity, cellular and molecular biology, life science research, scientific applications, clinical diagnostic, and training.
MARKET RESTRAINTS
The cell-free protein expression offers low protein production unsuitable for large industrial applications. This, in turn, is likely to hamper the growth of the market. Additionally, the high cost and short reaction scale of cell-free protein expression is expected to restrain the growth of the market over the forecast period.
MARKET GROWTH CHALLENGES
The cost of research activities involved in cell-free protein expression is significantly high. It may negatively impact the growth of the market. Also, a lack of effective post-translational modification systems in cell-free protein expression is expected to challenge the market’s growth over the forecast period.
CUMULATIVE GROWTH ANALYSIS
The report provides in-depth analysis of North America Cell Free Protein Expression market, market size, and compound annual growth rate (CAGR) for the forecast period of 2023-2029, considering 2022 as the base year. An increase in the prevalence of chronic disease has led to rise in demand for cell free protein expression technique in various applications, and therefore, the market is expected to witness growth at a specific CAGR from 2023-2029.
NORTH AMERICA CELL FREE PROTEIN EXPRESSION MARKET SEGMENTAL OVERVIEW
The North America Cell Free Protein Expression market comprises of different market segments like product, application, end users and country.
NORTH AMERICA CELL FREE PROTEIN EXPRESSION MARKET BY PRODUCT
By product, the North America Cell Free Protein Expression market includes the key segments like
- E. coli Cell-free Protein Expression System
- Wheat Germ Cell-free Protein Expression System
- Rabbit Reticulocytes Cell-free Protein Expression System
- Insect Cells Cell-free Protein Expression System
- Human Cell-free Protein Expression System
- Others
The E. coli cell-free protein expression system is expected to lead the market over the forecast period. E. coli cell-free protein expression systems can synthesize a broad variety of proteins, including soluble proteins such as enzymes or reporters, proteins with disulphide bonds such as antibodies and membrane proteins such as channels or transporter
The wheat germ cell-free protein expression system is expected to grow at the fastest rate during the forecast period. This system offers optimal environment for protein synthesis by allocating all metabolic resources to the protein in question, as opposed to basic cellular mechanisms. It is a key factor driving the growth of the segment.
NORTH AMERICA CELL FREE PROTEIN EXPRESSION MARKET BY APPLICATION
The North America Cell Free Protein Expression market finds key applications in
- Enzyme Engineering
- High Throughput Production
- Protein Labeling
- Protein-Protein Interaction
- Protein Purification
- Other Applications
The enzyme engineering segment is expected to dominate the market over the forecast period. Over the years, cell free protein expression method has become an established tool for rapid protein synthesis in order to accelerate the discovery of new enzymes and the development of proteins with improved characteristics. This is a key factor driving the growth of the segment.
High throughput production is expected to witness high growth over the forecast period. The cell free protein expression method is widely used in high-throughput functional genomics and proteomics, with significant advantages compared to protein expression in live cells
NORTH AMERICA CELL FREE PROTEIN EXPRESSION MARKET BY END USERS
The North America Cell Free Protein Expression market has major end users like
- Hospitals and Clinics
- Pharmaceutical and Biotechnology Companies
- Academic and Research Institutes
- Others
The pharmaceutical and biotechnology companies are expected to dominate the market over the forecast period. The expansion of current manufacturing capacities for biopharmaceuticals is stimulating demand for cell-free protein expression products. Also, high investment in biotechnology industries for the launch of innovative solutions is expected to drive the growth of the segment.
Furthermore, the academic and research institutes are expected to witness high growth over the forecast period due to rise in investments in R&D activities in proteomics and genomics.
NORTH AMERICA CELL FREE PROTEIN EXPRESSION MARKET BY COUNTRY
The North America Cell Free Protein Expression market is studied for the following countries
- United States
- Canada
- Mexico
United States is expected to dominate the market over the forecast period. The rise in prevalence of chronic diseases, along with technological advancements in genomic research, are key factors driving the growth of the market in the region.
Canada is anticipated to witness high growth during the estimated time period owing to technological advancements in drug discovery, the prevalence of chronic diseases, and a rise in R&D activities by several organizations.
COVID-19 IMPACT ANALYSIS ON NORTH AMERICA CELL FREE PROTEIN EXPRESSION MARKET
Axiom MRC provides a 360-degree analysis of micro and macro-economic factors in the North America Cell Free Protein Expression market. In addition, a complete analysis of changes on the North America Cell Free Protein Expression market expenditure, economic and international policies on supply and demand side is provided in this exclusive report. The report also studies the impact of pandemic on North America economies, international trade, business investments, GDP and marketing strategies of key players present in the market.
Due to the COVID-19 pandemic, there has been a significant disturbance in most industries across the globe. While a few industries experienced a contraction in their production and businesses, others faced severe outcomes such as the shutdown of businesses and movement restrictions. Due to the supply chain disruption, it has become difficult for manufacturers to produce and supply products.
The pandemic had a positive effect on the market. Biologists at Toronto University removed enzymes that were required for transcription and translation from E. coli to develop a cell-free expression system that identifies the parts of the SARS-CoV-2 genome and activates a molecular shift to generate a reporter protein, which eradicated the purification of RNA from sample replacing RT-PCR for additional rapid diagnostic testing. This development increased the acceptance of cell-free proteins in the diagnosis of COVID-19. This is expected to contribute to the growth of the market in the upcoming years.
COMPETITIVE LANDSCAPE ANALYSIS
The competitive landscape analysis of the North America Cell Free Protein Expression market is primarily focused on expanding the growth of the cell free protein expression industry in North America region with new product innovation, business expansion, increasing presence of a range of manufacturers operating in the cell free protein expression sector has led to growing demand for the market. Besides, the market offers a range of products in different applications to fulfil the required demand of consumer which further contributes healthy growth in the market.
The key players studied in market are
- Merck KGaA
- Cube Biotech GmbH
- CellFree Sciences Co., Ltd.
- Promega Corporation
- Thermo Fisher Scientific
- Creative Biolabs
- Bioneer Corporation
- Jena Bioscience GmbH
- New England Biolabs
- Biotechrabbit GmbH
- LenioBio GmbH
- Moderna Therapeutics
- GeneCopoeia, Inc
- Takara Bio
- Sutro Biopharma Inc
- Otsuka Holding Co. Ltd.
RECENT DEVELOPMENT:
January 2022: Thermo Fisher Scientific Inc. acquired PeproTech for approximately USD 1.85 billion. Through this acquisition, PeproTech's recombinant proteins portfolio will complement Thermo Fisher's cell culture media products and further enable Thermo Fisher to provide significant benefits to its customers through an integrated offering.
September 2021: Sutro Biopharma extended the cytokine derivative research program in partnership with Merck. Under the terms of this agreement, Merck and Sutro are performing preclinical R&D of cytokine derivatives using Sutro's exclusive site-specific conjugation and cell-free protein synthesis platforms, Xpress CF+ and XpressCF.
